- Human（1）
No data
- His Tag（1）
No data
- InsectCells（1）
No data
- Unconjugated（1）
No data
- RUO（1）
No data
- No（1）
No data
- 20ug/$245.00
- 500ug/$2225.00
No data
| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| Monoamine oxidase B | Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme) |  Human | InsectCells |  | SDS-PAGE | $245.00 20ug |
| 프로젝트 이름 | 약물 유형 | 치료 영역 | 적응증 | 단계 | 권리 지역 |
|---|---|---|---|---|---|
| Reversible MAOB Inhibitor | Small molecule | Neurological disease | Parkinson's disease | Phase I | Global |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate | P2B-001 | Phase 3 Clinical | Pharma Two B Ltd | Parkinson Disease | 상세 |
| Vafidemstat | ORY-2001 | Phase 2 Clinical | Oryzon Genomics Sa | Alzheimer Disease; Borderline Personality Disorder; Kabuki syndrome; Schizophrenia | 상세 |
| J-147 | J-147 | Phase 2 Clinical | Salk Institute | Alzheimer Disease; Ischemic Stroke | 상세 |
| Tisolagiline | KDS2010; KDS-2010 | Phase 2 Clinical | NeuroBiogen | Alzheimer Disease; Cognitive Dysfunction; Dementia; Obesity; Overweight | 상세 |
| Rasagiline transdermal patch (Teikoku Pharma) | Phase 1 Clinical | Teikoku Pharma | Parkinson Disease | 상세 | |
| SKL-PD | YKP-10461; SKL-PD | Phase 1 Clinical | SK Biopharmaceuticals Co Ltd | Parkinson Disease | 상세 |
| 18F-FCOB04 | 18F-FCOB04; 18F-FCOB-04 | Phase 1 Clinical | Peking Union Medical College Hospital | Neurodegenerative Diseases | 상세 |
| LNTH-2511 | Phase 1 Clinical | Lantheus Holdings Inc | Neuroinflammatory Diseases | 상세 | |
| Pramipexole and Rasagiline Mesylate Sustained-release Capsules(Zhejiang Jingxin Pharma) | Phase 1 Clinical | Zhejiang Jingxin Pharmaceutical Co Ltd | Parkinson Disease | 상세 | |
| Rasagiline Mesylate Sublingual membrane(Shanghai Shangyao Zhongxi Pharma) | Phase 1 Clinical | Shanghai Shangyao Zhongxi Pharmaceutical Co Ltd | Parkinson Disease | 상세 | |
| Rasagiline Mesylate Transdermal Patch(world leader) | Phase 1 Clinical | Guizhou Shiling Pharmaceutical Co Ltd, Shanghai World Ling Pharmaceutical Co Ltd | Parkinson Disease | 상세 | |
| HEC-122505MsOH | HEC-122505MsOH; HEC-122505-MsOH; HEC122505MsOH | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Parkinson Disease | 상세 |
| 18F-SMBT-1 | 18F-SMBT-1; 18-F-SMBT-1 | Clinical | Tohoku University | 상세 |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Rasagiline Mesylate | Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012 | Approved | Teva | Azilect, Agilect | EU | Parkinson Disease | Teva Bv | 2005-02-21 | Alzheimer Disease; Dementia; Multiple System Atrophy; Parkinson Disease; REM Sleep Behavior Disorder; Restless Legs Syndrome; Supranuclear Palsy, Progressive; Synucleinopathies | 상세 |
| Selegiline Hydrochloride | FPF-1100; E-250 (free base) | Approved | Sanofi | FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline | Mainland China | Parkinson Disease | Chinoin Pharmaceutical And Chemical Works Co Ltd | 1989-06-05 | Amphetamine-Related Disorders; Borderline Personality Disorder; Cocaine-Related Disorders; Cognition Disorders; Depressive Disorder, Major; HIV Infections; Marijuana Abuse; Parkinson Disease; Schizophrenia; Tobacco Use Cessation; Tobacco Use Disorder | 상세 |
| Safinamide Mesylate | PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125; PNU-151774; FCE-26743 | Approved | Newron Pharmaceutical | Xadago, Equfina | EU | Parkinson Disease | Zambon Spa | 2015-02-23 | Dyskinesia, Drug-Induced; Hepatic Insufficiency; Multiple System Atrophy; Parkinson Disease; Renal Insufficiency | 상세 |
